Opinion|Videos|June 27, 2024
CAR T-cell Therapy: Mechanisms of Actions of Brexucabtagene Autoleucel and Obecabtagene Autoleucel
Dr. Lori Muffly explains the general mechanism of action in CAR T-cell therapy and compares the distinct features of Brexucabtagene autoleucel (Brexu-cel), Tisagenlecleucel (Tisa-cel), and Obecabtagene autoleucel (Obe-cel).
Advertisement
Video content above is prompted by the following:
- What is the general mechanism of CAR T-cell therapy?
- What are the differences between the various CAR-Ts Brexucabtageneautoleucel (Brexu-cel), Tisagenlecleucel (Tisa-cel), and Obecabtageneautoleucel (Obe-cel)?
- Brexu-cel & Tisa-cel CAR-T Construct Design
- Obe-Cel CAT19-41BB-Z Fast Off Rate Design
- What are the differences between the various CAR-Ts Brexucabtageneautoleucel (Brexu-cel), Tisagenlecleucel (Tisa-cel), and Obecabtageneautoleucel (Obe-cel)?
Advertisement
Related to this article
ASCO issued an alert regarding dwindling supplies of ifosfamide, which is used across testicular cancer and sarcoma regimens.
The WVU Heart and Vascular Institute and WVU Cancer Institute performed West Virginia’s first single-port robotic-assisted thoracoscopic lobectomy.
The FDA approval of daraxonrasib was based on data from the phase 3 RASolute 302 trial in previously treated metastatic pancreatic ductal adenocarcinoma.
SOT106 earned an FDA fast track designation for advanced or recurrent soft tissue sarcoma.
The sNDA is supported by VIKTORIA-1 Study 2 data showing that gedatolisib-based regimens approximately doubled median PFS vs alpelisib plus fulvestrant.
Ivonescimab plus chemotherapy significantly improved overall survival vs durvalumab plus chemotherapy in advanced biliary tract cancer.
The pertuzumab biosimilar TQB2440 met equivalence margins for tpCR vs reference pertuzumab in ER/PR-negative, HER2-positive early breast cancer.
An OncLive Scientific Interchange and Workshop examined community integration of bispecific antibodies in multiple myeloma.
Advertisement
Advertisement
Trending on OncLive
1
FDA Approves Daraxonrasib for Metastatic Pancreatic Ductal Adenocarcinoma
2
Dr Reiss Binder on the FDA Approval of Daraxonrasib for Metastatic PDAC
3
ASCO Issues Warning Regarding Ifosfamide Shortage for Cancer Care
4
Dr Ayanambakkam on the Safety of Darlifarnib Plus Cabozantinib in RCC KD
5